Projects per year
Personal profile
Biography
Professor Jake Shortt is the Head of Haematology Research in the Department of Medicine at the School of Clinical Sciences and the Clinical Director of Monash Health Haematology. He is Principal Investigator on a range of clinical trials for T-cell lymphoma and myeloid malignancies, conducted through the Monash Haematology clinical trials unit.
Professor Shortt is the recipient of a National Health & Medical Research Council Emerging Leadership Fellowship. His translational work in the School of Clinical Sciences is focused on strategies incorporating epigenetic drugs with immunotherapy in haematological cancers, particularly lymphoma and multiple myeloma. He heads the Blood Cancer Therapeutics laboratory within the Monash Health Translation Precinct, facilitating bench-to-bedside research in order to progress these new treatments into the haematology clinic.
In addition to his clinical roles, Professor Shortt co-chairs the Monash Health Research Strategy and Governance Committee, is a member of the Barry Dalgeish Centre for Myeloma and Related Blood Cancers Scientific Advisory Committee and a member of the Cancer Council Victoria Research Subcommittee.
Clinical activities
Professor Shortt is the Clinical Director of Haematology services at Monash Health. His clinical trial portfolio includes studies in chronic myeloid leukaemia, myelodysplasia and T-cell lymphoma. He attends the Monash Haematology myeloid disorders clinic and looks after Haematology inpatients at Monash Health.
External positions
Honorary Clinical Professor, University of Melbourne
1 Jan 2022 → …
Honorary Principal Fellow, University of Melbourne
31 Jan 2019 → 31 Dec 2021
Honorary Senior Research Scientist, Peter MacCallum Cancer Centre
1 Oct 2015 → …
Consultant Haematologist, Monash Health
1 Feb 2008 → …
Research area keywords
- Cancer Immunology
- Epigenetics
- Leukemia
- Lymphoma
- Molecular Oncology
- Myelodysplasia
- Myeloma
- Thrombotic thrombocytopenic purpura
- cMYC
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being -
SDG 5 Gender Equality
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
PLATYPUS: Optimising platelet transfusions and medications to prevent bleeding in patients with bone marrow failure syndromes
Mo, A. (Primary Chief Investigator (PCI)), McQuilten, Z. (Chief Investigator (CI)), Wood, E. (Chief Investigator (CI)), Shortt, J. (Chief Investigator (CI)), Le, T. (Chief Investigator (CI)), Parker, C. (Chief Investigator (CI)), Fanning, L. (Chief Investigator (CI)), Wilson, K. (Chief Investigator (CI)), Nixon, J. (Chief Investigator (CI)), Kaplan, Z. (Associate Investigator (AI)), Brown, S. (Associate Investigator (AI)), Stanworth, S. (Associate Investigator (AI)), Estcourt, L. J. (Associate Investigator (AI)), Weinkove, R. (Associate Investigator (AI)) & Henden, A. (Associate Investigator (AI))
24/06/26 → 29/10/29
Project: Research
-
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Myeloid Leukemia
Shortt, J. (Primary Chief Investigator (PCI))
19/05/26 → 18/05/31
Project: Research
-
Leveraging investigator-initiated clinical trials and novel therapeutic strategies to improve outcomes of older adults with acute myeloid leukaemia.
Chua, C. (Primary Chief Investigator (PCI)) & Shortt, J. (Supervisor)
5/01/26 → 4/01/28
Project: Research
-
A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib (IVO) monotherapy and azacitidine (AZA) monotherapy in adult patients with hypomethylating agent (HMA) naive myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation (PyramIDH study).
Chua, C. (Primary Chief Investigator (PCI)) & Shortt, J. (Primary Chief Investigator (PCI))
19/02/25 → 18/02/30
Project: Research
-
ASCENDANCE - ASCiminib Evaluation in Newly diagnosed CML with Dasatinib to Augment response in Complex genomic Etiology
Shortt, J. (Primary Chief Investigator (PCI))
31/10/24 → 31/10/29
Project: Research
-
Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Susanto, O., Gruber, E. (Leading Author), Wun, C. M. (Leading Author), Franich, R. L., Ma, X., Sabouri-Thompson, Z., Porter, Z. J., Murray, H. C., Cluse, L. A., Maher, B., Brasacchio, D., Martin, B. P., Fraser, P. J., Nikolic, I., Arnau, G. M., Sandow, J. J., Simpson, K. J., Verrills, N. M., Johnstone, R. W. & Thompson, P. E. & 2 others, , 1 Mar 2026, In: Molecular Cancer Therapeutics. 25, 3, p. 416-434 19 p.Research output: Contribution to journal › Article › Research › peer-review
1 Link opens in a new tab Citation (Scopus) -
Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia
Gill, H. (Leading Author), Palandri, F., Ross, D. M., Göthert, J. R., Cochrane, T., Larsen, S. R., Halpern, A. B., Shortt, J., Rossetti, J. M., Liang, J., Marchetti, M., Wilson, A. J., Innes, A. J., Hanna, M., Vianelli, N., Stevenson, W. S., Vannucchi, A. M., Kleppe, M., Flynn, J. & Natsoulis, G. & 2 others, , 26 May 2026, In: Blood Advances. 10, 10, p. 3494-3504 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access5 Link opens in a new tab Citations (Scopus) -
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia
Yeung, D. T. (Leading Author), Grigg, A. P. (Leading Author), Reynolds, J. (Leading Author), Branford, S., Mazumdar, D., Cunningham, I., Shortt, J., Rowlings, P., Harrup, R., Ross, D. M., Kipp, D., Mills, A. K., Arthur, C. K., Schwarer, A., Jackson, K., Viiala, N., Weinkove, R., Yong, A. S. M., Gazdar, S. G. & White, D. & 3 others, , Feb 2026, In: British Journal of Haematology. 208, 2, p. 599-607 9 p.Research output: Contribution to journal › Article › Research › peer-review
2 Link opens in a new tab Citations (Scopus) -
The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time-driven activity-based costing study
Mo, A. (Leading Author), Haysom, H., Carrandi, A., de Albornoz, S. C., Guglielmino, J., Rushford, K., Ellison, A., Andrew, D., Jesurajah, A., Hu, E., Banahene, P., Hoo, L. S., Higgins, A. M., Shortt, J., Wood, E. M. & McQuilten, Z. K. (Leading Author), Jul 2026, In: British Journal of Haematology. 209, 1, p. 275-285 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Aligning kidney function assessment in patients with cancer to global practices in internal medicine
Sandhu, G., Adattini, J., Gordon, E. A., O'Neill, N., Bagnis, C., Chambers, P., Martin, J. H., Flynn, A., Ibrahim, K., Jardine, M. J., Johnson, D. W., Jones, G. R. D., Karapetis, C. S., Kelly, A., Kichenadasse, G., Kliman, D. S., Liauw, W., Lucas, C., Mallett, A. J. & Malyszko, J. & 15 others, , Apr 2025, In: eClinicalMedicine. 82, 11 p., 103102.Research output: Contribution to journal › Review Article › Research › peer-review
Open Access5 Link opens in a new tab Citations (Scopus)
Prizes
-
Albert Baikie Memorial Medal (2011)
Shortt, J. (Recipient), 2011
Prize: Prize (including medals and awards)
-
Joseph F Sambrook Prize for Research Excellence (2015)
Shortt, J. (Recipient), 2015
Prize: Prize (including medals and awards)
-
-
Prize for Preclinical Myeloma Research (2015)
Shortt, J. (Recipient), 2015
Prize: Prize (including medals and awards)
Activities
-
Cancer Council Victoria (External organisation)
Shortt, J. (Member)
2025 → …Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board
-
Australasian COVID19 Trial (ASCOT) Therapeutic Advisory Committee
Shortt, J. (Member)
2020 → 2022Activity: External Academic Engagement › Committees and working groups
-
Deputy Chair - ALLG Scientific Advisory Committee
Shortt, J. (Chair/ Co-Chair)
2020 → 2023Activity: External Academic Engagement › Committees and working groups
-
European Hematology Association (External organisation)
Shortt, J. (Member)
2018Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of networks of excellence
-
Standing Research Sub-Committee - Cancer Council Victoria
Shortt, J. (Member)
2017Activity: External Academic Engagement › Committees and working groups